Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORE001 (lidocaine)
- Development stage
- Phase 2
- Lead developer
- Orexa
- Modality
- Small Molecules
- Administration
- Oral[2][6]
01
Overview
Lidocaine (ORE001) is an oral small molecule formulation of the well-known local anesthetic and antiarrhythmic agent lidocaine, being developed by Orexa for the prevention and treatment of postoperative ileus. Unlike traditional uses of lidocaine (as an injectable or topical anesthetic), ORE001 is administered orally to modulate gastrointestinal function after surgery. Its mechanism involves inhibition of sodium channels, modulation of cell membrane permeability, and possible opioid receptor agonism. The drug aims to increase food intake and support recovery in patients post-surgery by reducing gastrointestinal disturbances that can delay recovery[1][3][4][5].
- Other names
- lidocaine oral formulation
02
Targets
MOR (Mu opioid receptor)SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on ORE001 (lidocaine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORE001 (lidocaine).